Impaired regulatory function in circulating CD4+CD25highCD127low/- T cells in patients with myasthenia gravis

Clinical Immunology

Volumn 145, Issue 3, 2012, Pages 209-223

  Thiruppathi, Muthusamy ^a   Rowin, Julie ^a   Ganesh, Balaji ^a   Sheng, Jian Rong ^a   Prabhakar, Bellur S ^a   Meriggioli, Matthew N ^a  

^a UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

Author keywords

Forkhead box protein P3 (FOXP3); Myasthenia gravis; ; Regulatory T cells;

Indexed keywords

AZATHIOPRINE; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; CYCLOSPORIN; IMMUNOGLOBULIN; INTERLEUKIN 7 RECEPTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYCLONAL ANTIBODY; PREDNISONE; PYRIDOSTIGMINE; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CD4+ CD25+ T LYMPHOCYTE; CELL ISOLATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOREGULATION; IN VITRO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; MYASTHENIA GRAVIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD4; CASE-CONTROL STUDIES; CELL SEPARATION; CYTOKINES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-7 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84867780260     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2012.09.012     Document Type: Article

References (54)

1. Meriggioli M.N., Sanders D.B. Myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009, 8:475-490.
2. Protti M.P., Manfredi A.A., Straub C., et al. Immunodominant regions for T helper-cell sensitization on the human nicotinic receptor alpha subunit in myasthenia gravis. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:7792-7796.
3. Wang Z.Y., Okita D.K., Howard J., et al. T-cell recognition of muscle acetylcholine receptor subunits in generalized and ocular myasthenia gravis. Neurology 1998, 50:1045-1054.
4. Bouneaud C., Kourilsky P., Buosso P. Impact of negative selection on the T cell repertoire reactive to a self peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 2000, 13:829-840.
5. Jiang H., Chess L. Regulation of immune responses by T cells. N. Engl. J. Med. 2006, 354:1166-1176.
6. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 2004, 22:531-562.
7. Jonuleit H., Schmitt E., Stassen M., et al. Identification and functional characterization of human CD4[+] CD25[+] T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 2001, 193:1285-1294.
8. Baecher-Allan C., Hafler D.A. Human regulatory T cells and their role in autoimmune disease. Immunol. Rev. 2006, 212:203-216.
9. Torgerson T.R. Regulatory T cells in human autoimmune diseases. Springer Semin. Immunopathol. 2006, 28:63-76.
10. Fattorossi A., Battaglia A., Buzzonetti A., et al. Circulating and thymic CD4+ CD25+ T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. Immunology 2005, 116:134-141.
11. Li X., Xiao B.G., Xi J.Y., et al. Decrease of Foxp3+ regulatory T cells and elevation of CD19+ BAFF-R+ B cells and soluble ICAM-1 in myasthenia gravis. Clin. Immunol. 2008, 126:180-188.
12. Masuda M., Matsumoto M., Tanaka S., et al. Clinical implication of peripheral CD4+ CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients. J. Neuroimmunol. 2010, 225:123-131.
13. Zhang Y., Wang H., Chi L., et al. The role of FoxP3+CD4+CD25hi Tregs in the pathogenesis of myasthenia gravis. Immunol. Lett. 2009, 122:52-57.
14. Huang Y.M., Pirskanen R., Giscombe R., et al. Circulating CD4+CD25- and CD4+CD25+ Tcells in myasthenia gravis and in relation to thymectomy. Scand. J. Immunol. 2004, 59:408-414.
15. high regulatory cells in human peripheral blood. J. Immunol. 2001, 167:1245-1253.
16. + regulatory T cells express lower levels of the IL-7 receptor α chain [CD127], allowing consistent identification and sorting of live cells. J. Immunol. Methods 2007, 319:41-52.
17. Seddiki N., Santner-Nanan B., Martinson J., et al. Expression of interleukin [IL]-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 2006, 203:1693-1700.
18. Jaretski A., Barohn R.J., Ernstoff R.M., et al. Myasthenia gravis: recommendations for clinical research standards. Task force of the Medical and Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000, 55:16-23.
19. Sanders D.B., Tucker-Lipscomb B., Massey J.M. A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score. Ann. N. Y. Acad. Sci. 2003, 998:440-444.
20. Harcourt G.C., Sommer N., Rothbard J., et al. A juxta-membrane epitope on the human acetylcholine receptor recognized by T cells in myasthenia gravis. J. Clin. Invest. 1988, 82:1295-1300.
21. Brocke S., Brautbar C., Steinman L., et al. In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. J. Clin. Invest. 1988, 82:1894-1900.
22. Venken K., Thewissen M., Hellings N., et al. A CFSE based assay for measuring CD4+ CD25+ regulatory T cell suppression of auto-antigen specific and polyclonal T cell responses. J. Immunol. Methods 2007, 322:1-11.
23. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 2003, 4:330-336.
24. + human T regulatory cells during in vitro expansion. Blood 2012, 119:2810-2818.
25. Booth N.J., McQuaid A.J., Sobande T., et al. Different proliferative potential and migratory characteristics of human CD4+ regulatory T cells that express either CD45RA or CD45RO. J. Immunol. 2010, 184:4317-4326.
26. Valmori D., Merlo A., Souleimanian N.E., et al. A peripheral circulating compartment of natural naïve CD4 Tregs. J. Clin. Invest. 2005, 115:1953-1962.
27. Seddiki N., Santner-Nanan B., Tangye S.G., et al. Persistence of naïve CD45RA+ regulatory T cells in adult life. Blood 2006, 107:2830-2838.
28. Vukmanovic-Stejic M., Zhang Y., Cook J.E., et al. Human CD4+ CD25hiFoxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J. Clin. Invest. 2006, 116:2423-2433.
29. Baecher-Allan C., Wolf E., Hafler D.A. MHC class II expression identifies functionally distinct human regulatory T cells. J. Immunol. 2006, 176:4622-4631.
30. Sansom D.M., Walker L.S. The role of CD28 and cytotoxic T lymphocyte antigen-4 [CTLA-4] in regulatory T-cell biology. Immunol. Rev. 2006, 212:131-148.
31. Jian N., Nguyen H., Chambers C., et al. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1524-1528.
32. Moes N., Rieux-Laucat F., Begue B., et al. Reduced expression of FOXP3 and regulatory T-cell function in severe forms of early-onset autoimmune enteropathy. Gastroenterology 2010, 139:770-778.
33. high T regulatory cell function in patients with active systemic lupus erythematosus. J. Immunol. 2007, 178:2579-2588.
34. high regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 2008, 123:79-89.
35. Matsui N., Nakane S., Saito F., et al. Undiminished regulatory T cells in the thymus of patients with myasthenia gravis. Neurology 2010, 74:816-820.
36. Michel L., Berthelot L., Pettré S., et al. Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis. J. Clin. Invest. 2008, 118:3411-3419.
37. Brusko T., Wasserfall C., McGrail K., et al. No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes 2007, 56:604-612.
38. Killebrew J.R., Perdue N., Kwan A., et al. A self-reactive TCR drives the development of Foxp3+ regulatory T cells that prevent autoimmune disease. J. Immunol. 2011, 187:861-869.
39. Gambineri E., Torgerson T.R., Ochs H.D. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance, a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T cell homeostasis. Curr. Opin. Rheumatol. 2003, 15:430-435.
40. Zhang L., Zhao Y. The regulation of Foxp3 expression in regulatory CD4[+]CD25[+]T cells: multiple pathways on the road. J. Cell. Physiol. 2007, 211:590-597.
41. Chauhan S.K., Saban D.R., Lee H.K., et al. Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation. J. Immunol. 2009, 182:148-153.
42. Balandina A., Lécart S., Dartevelle P., et al. Functional defect of regulatory CD4+CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 2005, 105:735-741.
43. Bacchetta R. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J. Clin. Invest. 2006, 116:1713-1722.
44. Takahashi T., Tagami T., Yamazaki S., et al. Immunologic self-tolerance maintained by CD25[+]CD4[+] regulatory T cells constitutively expressing cytotoxic T lymphocyte associated antigen 4. J. Exp. Med. 2000, 192:303-310.
45. Marson A., Kretschmer K., Frampton G.M., et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007, 445:931-935.
46. Zheng Y., Josefowicz S.Z., Kas A., et al. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 2007, 445:936-940.
47. Aricha R., Mizrachi K., Fuchset S., et al. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J. Autoimmun. 2011, 36:135-141.
48. Fujimoto M., Nakano M., Terabe F., et al. The influence of excessive Il-6 production in vivo on the development and function of Foxp3+ regulatory T cells. J. Immunol. 2011, 186:32-40.
49. + regulatory T cells in humans. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4793-4798.
50. + regulatory T cells. J. Immunol. 2006, 177:5296-5306.
51. Sheng J.R., Li L.C., Ganesh B.B., et al. Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia. Clin. Immunol. 2008, 128:172-180.
52. Sheng J.R., Muthusamy T., Prabhakar B.S., et al. GM-CSF-induced regulatory T cells inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravis. J. Neuroimmunol. 2011, 240-241:65-73.
53. Luther C., Adamopoulou E., Stoeckle C., et al. Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients. J. Immunol. 2009, 83:841-848.
54. Vrolix K., Fraussen J., Molenaar P.C., et al. The auto-antigen repertoire in myasthenia gravis. Autoimmunity 2010, 43:380-400.